Literature DB >> 25163770

Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.

S Peraramelli1, S Thomassen, A Heinzmann, J Rosing, T M Hackeng, R Hartmann, F Scheiflinger, M Dockal.   

Abstract

BACKGROUND: TFPI is a Kunitz-type protease inhibitor that downregulates the extrinsic coagulation pathway by inhibiting factor Xa (FXa) and FVIIa. All three Kunitz domains (KD1, KD2, and KD3) and protein S are required for optimal inhibition of FXa and FVIIa. There is limited information on Kunitz domain requirements of the inhibition of TF:FVIIa-catalyzed FIX and FX activation by TFPI. AIM: To investigate the role of the Kunitz domains of TFPI and protein S in the inhibition of FX and FIX activation.
METHODS: Inhibition of TF:FVIIa-catalyzed FX and FIX activation by full-length TFPI (TFPIFL ) and TFPI constructs was quantified from progress curves of FXa and FIXa generation measured with chromogenic substrates. RESULTS AND
CONCLUSIONS: TFPIFL inhibited TF:FVIIa-catalyzed FIX activation with a Ki of 16.7 nmol L(-1) . Protein S reduced the Ki to 1.0 nmol L(-1) . TFPI1-150 and KD1-KD2 had 10-fold higher Ki values and were not stimulated by protein S. Single Kunitz domains were poor inhibitors of TF:FVIIa-catalyzed FIX activation (Ki >800 nm). FX activation was measured at limiting FVIIa and excess TF or vice versa. At both conditions, TFPIFL , TFPI1-150 , and KD1-KD2 showed similar inhibition of FX activation. However, at low phospholipid concentrations, TFPIFL was ~ 15-fold more active than TFPI1-150 or KD1-KD2. Apparently, excess phospholipids act as a kind of sink for TFPIFL , limiting its availability for TF:FVIIa inhibition. Preformed FXa:TFPIFL/1-150 complexes rapidly and stoichiometrically inhibited FIX and FX activation by TF:FVIIa, indicating that binary TFPI:FXa complex formation is the limiting step in TF:FVIIa inhibition. Protein S also enhanced inhibition of TF:FVIIa-catalyzed FX activation by TFPI.
© 2014 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  TFPI; factor IX; factor X; phospholipids; protein S

Mesh:

Substances:

Year:  2014        PMID: 25163770     DOI: 10.1111/jth.12713

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

Review 1.  New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.

Authors:  Margaret V Ragni
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

2.  Identification of a new adtrp1-tfpi regulatory axis for the specification of primitive myelopoiesis and definitive hematopoiesis.

Authors:  Li Wang; Xiaojing Wang; Longfei Wang; Muhammad Yousaf; Jia Li; Mengxia Zuo; Zhongcheng Yang; Dongzhi Gou; Binghao Bao; Lei Li; Ning Xiang; Haibo Jia; Chengqi Xu; Qiuyun Chen; Qing Kenneth Wang
Journal:  FASEB J       Date:  2017-09-06       Impact factor: 5.191

Review 3.  Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy.

Authors:  Margaret V Ragni
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.

Authors:  Pansakorn Tanratana; Paul Ellery; Pamela Westmark; Alan E Mast; John P Sheehan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-02       Impact factor: 8.311

5.  New Functional Tools for Antithrombogenic Activity Assessment of Live Surface Glycocalyx.

Authors:  Sashka Dimitrievska; Liqiong Gui; Amanda Weyers; Tylee Lin; Chao Cai; Wei Wu; Charles T Tuggle; Sumati Sundaram; Jenna L Balestrini; David Slattery; Lise Tchouta; Themis R Kyriakides; John M Tarbell; Robert J Linhardt; Laura E Niklason
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-07       Impact factor: 8.311

6.  Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results.

Authors:  Ryuta Miyake; Yuki Yamada; Shoichiro Yamanaka; Ryuji Kawaguchi; Norihisa Ootake; Shohei Myoba; Hiroshi Kobayashi
Journal:  Mol Clin Oncol       Date:  2021-12-23

7.  Studies on activation and regulation of the coagulation cascade in chronic rhinosinusitis with nasal polyps.

Authors:  Ping-Ping Cao; Bao-Feng Wang; James E Norton; Lydia A Suh; Roderick G Carter; Whitney W Stevens; Anna G Staudacher; Julia H Huang; Kathryn E Hulse; Anju T Peters; Leslie C Grammer; David B Conley; Kevin C Welch; Robert C Kern; Zheng Liu; Jingying Ye; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2022-03-07       Impact factor: 14.290

8.  Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.

Authors:  Salvatore Santamaria; Natalia Reglińska-Matveyev; Magdalena Gierula; Rodney M Camire; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

9.  Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP.

Authors:  Adrienn Teraz-Orosz; Magdalena Gierula; Anastasis Petri; David Jones; Renos Keniyopoullos; Patricia Badia Folgado; Salvatore Santamaria; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  Blood Adv       Date:  2022-01-25

10.  Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.

Authors:  Björn Dahlbäck; Li Jun Guo; Ruzica Livaja-Koshiar; Sinh Tran
Journal:  Res Pract Thromb Haemost       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.